|
|||||
|
|
Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C‐III |
|
| Authors: | M. Ghosh Laskar M. Eriksson M. Rudling B. Angelin |
| Affiliation: | 1. Metabolism Unit, Department of Endocrinology, Metabolism and Diabetes, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden;2. Molecular Nutrition Unit, Center for Innovative Medicine (CIMED), Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden;3. KI/AZ Integrated CardioMetabolic Center (ICMC), Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden |
| Abstract: | |
| Keywords: | apolipoprotein chenodeoxycholic acid LDL cholesterol LDL receptors lipoprotein(a) PCSK9 |